JUL 17, 2018 01:35 PM PDT

First Drug for Smallpox Treatment

WRITTEN BY: Nouran Amin

TPOXX (tecovirimat), the first drug with an indication for treatment of smallpox, was just approved by the U.S. Food and Drug Administration to SIGA Technologies Inc. The development of TPOXX was in conjunction with the U.S. Department of Health and Human Services’ Biomedical Advanced Research and Development Authority (BARDA).

Even though eradicated in 1980, the World Health Organization (WHO) announced that smallpox as a contagious and sometimes fatal infectious disease that can be used as a bioweapon.

“To address the risk of bioterrorism, Congress has taken steps to enable the development and approval of countermeasures to thwart pathogens that could be employed as weapons. Today’s approval provides an important milestone in these efforts. This new treatment affords us an additional option should smallpox ever be used as a bioweapon,” said FDA Commissioner Scott Gottlieb, M.D. "This is the first product to be awarded a Material Threat Medical Countermeasure priority review voucher. Today’s action reflects the FDA’s commitment to ensuring that the U.S. is prepared for any public health emergency with timely, safe and effective medical products.”

Before its 1980 eradication, variola virus, the virus that leads to smallpox, it was mainly spread by direct contact between people. The symptoms typically began 10 to 14 days after infection and include fever, exhaustion, headache, and backache followed by a rash initially with small, pink bumps progressed to pus-filled sores before finally crusting over and scarring. Smallpox complications include encephalitis (inflammation of the brain), corneal ulcerations (an open sore on the clear, front surface of the eye) and blindness.

The efficacy of TPOXX against smallpox was concluded by studies on animals infected with viruses that are closely related to the virus that results in smallpox and was based on measuring survival at the end of the studies. The studies showed that the animals treated with TPOXX have survived compared to the animals treated with a placebo.

Using the FDA’s Animal Rule, which ensures efficacy are adequate from well-controlled animal research findings, TPOXX was approved.

TPOXX safety was evaluated using clinical trials on 359 healthy human volunteers without a smallpox infection and the most frequently reported side effects included a headache, nausea, and abdominal pain. Additionally, TPOXX received the Orphan Drug designation, which allows incentives to assist and inspire the development of drugs for rare diseases and a Material Threat Medical Countermeasure Priority Review Voucher, which provides additional incentives for specific medical products intended to treat or prevent harm from specific chemical, biological, radiological and nuclear threats.

 

About the Author
  • Nouran enjoys writing on various topics including science & medicine, global health, and conservation biology. She hopes through her writing she can make science more engaging and communicable to the general public.
You May Also Like
SEP 15, 2019
Drug Discovery
SEP 15, 2019
Effective Treatment for Ulveal Melanoma
Uveal melanoma is a rare and aggressive type of melanoma that targets the eye and affects an estimated 2,500 people in the United States annually. Nearly h...
SEP 15, 2019
Drug Discovery
SEP 15, 2019
Anti-cancer Drug Disguises as Fat
According to a study published in the Journal of the American Chemical Society (JACS), a new drug-delivery system disguises as fat in order to outsmart tum...
SEP 15, 2019
Drug Discovery
SEP 15, 2019
MDMA Treats Social Anxiety in Autistic Adults
People with autism are more likely than those without to develop social anxiety (Bejerot: 2014). Meanwhile, current anti-anxiety medications and therapeuti...
SEP 15, 2019
Genetics & Genomics
SEP 15, 2019
New Gene Editing Technology to Combat Hereditary Diseases
Until recently, many types of gene-editing methods were unable to target critical parts of DNA. Now however, researchers at the Salk Institute have develop...
SEP 15, 2019
Drug Discovery
SEP 15, 2019
Drug Reduces Heart Attacks in Diabetic Patients
Recent results from a clinical trial that evaluated the addition of a drug called ‘ticagrelor’ to aspirin were shown to improve clinical outcom...
SEP 15, 2019
Drug Discovery
SEP 15, 2019
Diabetic Drugs Offer Protection Against Kidney Failure
Kidney failure is a consequence of diabetic kidney disease--roughly 3 million people are seeking treatment worldwide for kidney failure and the numbers are...
Loading Comments...